Biopharmaceutical giant Amgen has announced an additional $300 million investment in its manufacturing site in Juncos, Puerto Rico. This latest outlay brings the company’s total commitment to its U.S. operations to nearly $2 billion over the past year.
Strengthening the domestic supply chain The Juncos facility, established in 1992, is a cornerstone of Amgen’s global production network, serving over 60 countries.
-
Investment objectives: The extra funding will bolster biologics production capacity and support the development of a highly skilled local workforce.
-
Political context: This move comes as pharmaceutical companies navigate evolving import tariff proposals and “Most Favored Nation” (MFN) drug pricing agreements with the White House. Expanding operations in U.S. territories like Puerto Rico allows firms to ensure the resilience of their domestic supply chains.
Amgen’s broader investment landscape In addition to the Puerto Rico project (now totaling nearly $1 billion), Amgen is moving forward with several other major infrastructure initiatives:
-
Ohio: A $900 million expansion of its biomanufacturing plant.
-
California: A $600 million R&D center in Thousand Oaks designed to accelerate next-generation drug discovery.
Economic and employment impact Amgen leadership emphasized that these projects not only ensure patient access to essential medicines but also generate hundreds of new jobs in construction and advanced manufacturing. Aggressive investment in domestic production is viewed as a long-term strategy to reinforce the U.S. biopharmaceutical industry amidst international trade fluctuations.